Get the Stockscreener App
40.03
1.22%
-0.495
After Hours:
39.50
-0.53
-1.32%
Indivior Pharmaceuticals Inc stock is traded at $40.03, with a volume of 995.76K.
It is down -1.22% in the last 24 hours and down -4.30% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$40.52
Open:
$40.62
24h Volume:
995.76K
Relative Volume:
0.52
Market Cap:
$4.73B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
20.27
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+2.33%
1M Performance:
-4.30%
6M Performance:
+15.23%
1Y Performance:
+133.55%
1-Day Range:
$40.01
$40.99
1-Week Range:
$38.56
$40.99
52-Week Range:
$16.69
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
40.03 | 4.79B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indivior Pharmaceuticals, Inc. Revenue Breakdown – DUS:E7P - TradingView
Indivior PLC (INDV) Institutional Confidence - TradingKey
Indivior Announces Date and Time for Second Quarter 2026 Financial Results and Conference Call - Quiver Quantitative
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast - The Manila Times
Indivior Leadership to Host Aug. 4 Webcast After Q2 Results - Stock Titan
Indivior to report Q2 2026 results, host webcast presentation - Bitget
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Striking Potential with a 29.94% Upside - DirectorsTalk Interviews
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.5% -- What GF Score of 69 Tells Investors - GuruFocus
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score - ChartMill
Price to earnings forward of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares in planned trade - Stock Titan
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com - Investing.com Nigeria
INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value - Stock Titan
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
How Indivior’s Multi-Index Russell 2000 Defensive Inclusion (INDV) Has Changed Its Investment Story - simplywall.st
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
Is Indivior Pharmaceuticals (INDV) Fully Valued As Russell 2000 Index Additions Draw Buyers? - simplywall.st
Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable - MSN
Indivior Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Indivior’s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV) - Yahoo Finance
Indivior added to Russell 2000 defensive indices, shares gain visibility with US investors - ad-hoc-news.de
Does Indivior (INDV) Joining Multiple Russell 2000 Defensive Indices Recast Its Opioid-Treatment Narrative? - simplywall.st
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS: INDV) added to Russell 2000 Defensive Index - marketscreener.com
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny - Ad-hoc-news.de
INDV Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Indivior Pharmaceuticals, Inc. Actuals & Estimates (LS:A42086) - TradingView
Indivior Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INDV) - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Is Big Pharma's Patent Cliff Driving a New M&A Wave - Kavout | AI
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
E7P Forecast — Price Target — Prediction for 2027 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
Reasons Why Investors Should Consider Betting on Indivior Stock - The Globe and Mail
A42086 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Australia
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):